Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Atara Biotherapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 43 | 37 | −6 |
| Shares | 2.37M | 2.09M | −281.6K (−11.9%) |
| Value | $31.5M | $12.4M | −$19.1M (−60.7%) |
New holders (5)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 41,014 | $243.6K | 0.00% |
| Gsa Capital Partners LLP | 19,385 | $115.0K | 0.01% |
| Boston Private Wealth LLC | 421 | $2.50K | 0.00% |
| Raiffeisen Bank International AG | 200 | $1.19K | 0.00% |
| Barclays PLC | 1 | $6 | 0.00% |
Sold out (11)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Citadel Advisors LLC | 267,353 | $3.56M |
| Marshall Wace, LLP | 24,958 | $332.2K |
| Cubist Systematic Strategies, LLC | 12,682 | $168.8K |
| Millennium Management LLC | 10,133 | $134.9K |
| Point72 Asia (Singapore) Pte. Ltd. | 3,603 | $48.0K |
| R Squared Ltd | 240 | $3.19K |
| Point72 (DIFC) Ltd | 68 | $905 |
| GAMMA Investing LLC | 56 | $745 |
| EverSource Wealth Advisors, LLC | 35 | $466 |
| Alexis Investment Partners, LLC | 28 | $373 |
| Citigroup Inc | 2 | $27 |